---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-060893"
form_type: "8-K"
ticker: "IMNM"
cik: "0001472012"
company_name: "Immunome Inc."
filed_at: "2024-05-14T23:59:59+00:00"
generated_at: "2026-06-02T00:41:05.992931+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Immunome reports Q1 net loss $129.5M; cash $309.7M extends into 2026; AL102 topline data H2 2025

## Summary
- Net loss of $129.5M ($2.51 diluted EPS) includes $112.0M in IPR&D expenses from AL101/AL102 and IM-1021 acquisitions.
- Cash, cash equivalents and marketable securities $309.7M as of March 31, 2024; runway expected into 2026.
- R&D expense $15.4M; G&A expense $6.0M, including $1.8M stock-based compensation.
- Phase 3 RINGSIDE Part B for AL102 fully enrolled; topline data expected second half 2025.
- IND submissions for IM-1021 (ROR1 ADC) and IM-3050 (FAP-targeted RLT) expected Q1 2025.

## SEC filing metadata
- accession: 0001104659-24-060893
- form_type: 8-K
- ticker: IMNM
- cik: 0001472012
- company_name: Immunome Inc.
- filed_at: 2024-05-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1472012/000110465924060893/0001104659-24-060893-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1472012/000110465924060893/tm2414252d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-060893
- JSON: https://secwatch.observer/filing/0001104659-24-060893.json
- Plain text: https://secwatch.observer/filing/0001104659-24-060893.txt

## Key facts
- Earnings Releases
  Immunome Inc. reported first quarter ended March 31, 2024 results: net income net loss of $129.5 million, EPS basic and diluted net loss per share attributable to common stockholders of $2.51.
  - Period: first quarter ended March 31, 2024
  - Net income: net loss of $129.5 million
  - EPS: basic and diluted net loss per share attributable to common stockholders of $2.51
  - Result: reported results
  source text: Immunome, Inc. (the “Company”) announced its financial results for the first quarter ended March 31, 2024
  evidence_url: https://www.sec.gov/Archives/edgar/data/1472012/000110465924060893/0001104659-24-060893-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.